Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Amphiregulin as a monitoring biomarker during treatment of acute GvHD

Shernan Holtan • 25 Apr 2022
The 2022 Tandem Meetings
General Human chorionic gonadotropin Ruxolitinib
REACH2

Shernan Holtan, MD, University of Minnesota, Minneapolis, MN, comments on the potential of amphiregulin as a biomarker to monitor patients during treatment of acute graft-versus-host disease (GvHD). Using samples collected from two prospective clinical trials, it was found that amphiregulin levels decreased in patients responding to treatment. This biomarker could be useful in clinical practice to monitor patients and determine whether a patient’s symptoms are related to GvHD or not. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Shernan Holtan

Post-transplant cyclophosphamide, tacrolimus, and MMF for GvHD in the myeloablative setting
0:43
Post-transplant cyclophosphamide, tacrolimus, and MMF for GvHD in the myeloablative setting
Shernan Holtan • 10 Dec 2022
Unmet needs in GvHD & the promise of regenerative medicine
1:05
Unmet needs in GvHD & the promise of regenerative medicine
Shernan Holtan • 10 Dec 2022
How GvHD impacts patient quality of life
0:58
How GvHD impacts patient quality of life
Shernan Holtan • 10 Dec 2022
ASH 2022 LBA: post-transplant cyclophosphamide, tacrolimus & MMF for GvHD prophylaxis in RIC
1:15
ASH 2022 LBA: post-transplant cyclophosphamide, tacrolimus & MMF for GvHD prophylaxis in RIC
Shernan Holtan • 10 Dec 2022

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI for clinical decision-making
2:25
Addressing the risk of over-reliance on AI for clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Telomere dynamics in normal and pathological aging
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals